Dr. Martin on the Role of Maintenance Therapy With Rituximab in MCL

In Partnership With:

Peter Martin, MD, discusses the role of maintenance therapy with rituximab in mantle cell lymphoma.

Peter Martin, MD, chief of the Lymphoma Program at the Meyer Cancer Center and an associate professor of medicine at Weill Cornell Medicine, discusses the role of maintenance therapy with rituximab (Rituxan) in mantle cell lymphoma (MCL).

Improved overall survival has been demonstrated with rituximab maintenance following R-CHOP–based therapy, as well as following autologous stem cell transplant, says Martin. However, the role of rituximab maintenance after bendamustine-based therapy had not been fully realized, Martin adds.

During the 2021 ASCO Annual Meeting, findings from a retrospective, real-world analysis demonstrated that bendamustine/rituximab was the most used first-line therapy for patients with MCL in community-based practices in the United States. Additionally, the data suggested that rituximab maintenance following treatment yielded superior outcomes in patients, Martin says. As such, all patients should receive rituximab maintenance after bendamustine-based induction therapy unless they have contraindications, concludes Martin.

Related Videos
Brian Henick, MD
Abhinav Deol, MD
Veronika Bachanova, MD, PhD
Walter M. Stadler, MD
Susan Domchek, MD, FASCO
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Amy L. Cummings, MD, thoracic oncologist, assistant professor of medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Related Content